Sinjard 25

• Glycemic control in type 2 diabetes mellitus
• Reduction of cardiovascular death in type 2 diabetes with established cardiovascular disease

Empagliflozin is a sodium glucose co-transporter-2 (SGLT-2) inhibitor. SGLT2 co-transporters are responsible for reabsorption of glucose from the glomerular filtrate in the kidney. SGLT2 inhibition reduces renal absorption and lowers renal threshold for glucose, resulting in increased glucose excretion, reduced hyperglycemia, weight loss, and reduced blood pressure.

Adult Dose: 10 mg once daily in the morning, may be increased to 25 mg if needed.

Renal Dose: CrCl <45 mL/min: Contraindicated. <60 mL/min: Max 10 mg daily.

Common Side Effects:

• Urinary tract infections
• Female genital mycotic infections
• Dehydration
• Hypotension
• Weakness
• Dizziness
• Increased thirst

Empagliflozin may be unsafe during pregnancy. Animal studies have shown harmful effects. Doctor will weigh benefits and risks.

• Empagliflozin is used alone or with other diabetes medicines to control blood sugar.
• It may cause loss of too much fluid (dehydration) or frequent urination. Drink plenty of water and stay hydrated.
• May cause hypoglycemia when used with other antidiabetic medicines, alcohol or if meals are skipped. Carry sugary food or fruit juice with you.
• Can cause genital fungal and/or urinary tract infections in both females and males; practice good hygiene.
• Monitor blood sugar regularly.
• Inform doctor if you experience constant dizziness, joint pain, cold-like symptoms or unexplained nausea/vomiting.

In the event of overdose, usual supportive measures should be employed. Removal by hemodialysis has not been studied.

Store below 30°C, protected from light & moisture. Keep out of reach of children.